SCHEDULE: Commodore Capital Boosts Relay Therapeutics Stake
Beneficial Ownership Report
Commodore Capital LP and its affiliates reported a 7.8% beneficial ownership stake in Relay Therapeutics, Inc., holding 13,350,000 shares of common stock as of June 30, 2025.
Summary
- Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 13,350,000 shares of Relay Therapeutics, Inc. Common Stock.
- This ownership represents 7.8% of the total outstanding Common Stock of Relay Therapeutics, Inc.
- The percentage is calculated based on 171,692,132 Common Shares reported as issued and outstanding as of June 30, 2025, in Relay Therapeutics' Quarterly Report on Form 10-Q filed on August 7, 2025.
- Commodore Capital LP serves as the investment manager to Commodore Capital Master LP.
- Robert Egen Atkinson and Michael Kramarz are the managing partners of Commodore Capital LP and exercise investment discretion over these securities.
- The shares were not acquired and are not held for the purpose or with the effect of changing or influencing the control of Relay Therapeutics, Inc.
Sentiment
Score: 5
Explanation: Neutral, as this is a standard beneficial ownership disclosure and does not contain performance or forward-looking statements that would indicate a positive or negative sentiment.
Positives
- The filing indicates continued significant institutional investment in Relay Therapeutics, Inc. by Commodore Capital and its affiliates.
Future Outlook
This filing is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.
Industry Context
This filing reflects ongoing institutional investor interest in the biotechnology and pharmaceutical sectors, with a notable stake in Relay Therapeutics, a company focused on precision medicine.
Stakeholder Impact
- Shareholders may view this significant institutional stake as a sign of confidence in Relay Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (beneficial ownership snapshot date). |
| 08/07/2025 | Date Relay Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, which provided the total shares outstanding used for ownership percentage calculation. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Relay Therapeutics, Common Stock, Beneficial Ownership, Schedule 13G, Institutional Investor, Commodore Capital, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.